Aberrant activation from Receptor Tyrosine Kinases (RTKs) allows cancer cells to abnormally control the cellular processes of survival, proliferation, and cell death, leading to tumorigenesis and drug resistance [28–30]. Here, NTRK1 is linked to cancer.